Journal of Cellular Physiology

Cover image for Vol. 230 Issue 11

Edited By: Gary S. Stein, Harvey M. Florman and Constance E. Brinckerhoff

Impact Factor: 3.839

ISI Journal Citation Reports © Ranking: 2014: 15/83 (Physiology); 71/184 (Cell Biology)

Online ISSN: 1097-4652

Recently Published Issues

See all

Top Cited Articles 2014

Franchina, T., Amodeo, V., Bronte, G., Savio, G., Ricciardi, G. R.R., Picciotto, M., Russo, A., Giordano, A. and Adamo, V.
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
Journal of Cellular Physiology 2014, vol. 229, p. 97

Basile, D. P. and Yoder, M. C.
Circulating and Tissue Resident Endothelial Progenitor Cells
Journal of Cellular Physiology 2014, vol. 229, p. 10

Anderson, M., Roshanravan, H., Khine, J. and Dryer, S. E.
Angiotensin II Activation of TRPC6 Channels in Rat Podocytes Requires Generation of Reactive Oxygen Species
Journal of Cellular Physiology 2014, vol. 229, p. 434

Zhang, Y.-Y., Yue, J., Che, H., Sun, H.-Y., Tse, H.-F. and Li, G.-R
BKCa and hEag1 Channels Regulate Cell Proliferation and Differentiation in Human Bone Marrow-Derived Mesenchymal Stem Cells
Journal of Cellular Physiology 2014, vol. 229, p. 202

Basile, D. P. and Yoder, M. C.
Circulating and Tissue Resident Endothelial Progenitor Cells
Journal of Cellular Physiology 2014, vol. 229, p. 10

See More Here

SEO Tips for Authors

SEO Author

JCP Spotlight Article

Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer

Zoran Culig

Androgen receptor (AR) is a key factor in regulation of growth and differentiation in normal and malignant prostate. Endocrine therapies for prostate cancer include inhibition of androgen production either by analogues of luteinizing hormone releasing hormone or abiraterone acetate and/or use of anti-androgens such as hydroxyflutamide, bicalutamide, and enzalutamide. Castration therapy-resistant cancer develops inevitably in patients who undergo treatment. AR coactivators are proteins which interact with one or more regions of the AR thus enhancing its function. Although several functions of AR coactivators may be redundant, specific functions have been identified and analyzed. The p160 group of coactivators, SRC-1, -2, and -3 not only potentiate the activation of the AR, but are also implicated in potentiation of function of insulin-like growth factor-I and activation of the Akt pathway. Transcriptional integrators p300 and CBP are up-regulated by androgen ablation and may influence antagonist/agonist balance of non-steroidal anti-androgens. A therapy approach designed to target p300 in prostate cancer revealed its role in regulation of proliferation of migration of androgen-sensitive and –insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine that is overexpressed in castration-therapy resistant prostate cancer. Some coactivators, such as Vav3 are involved in regulation of transcriptional activity of truncated AR, which emerge during endocrine therapy. Stimulation of cellular migration and invasion by AR coactivators has also been described. Translational studies with aim to introduce anti-AR coactivator therapy have not been successfully implemented in the clinic so far.

Freely Available for A Limited Time

Read

PHYSIOLOGY EcThis content will be freely available to all through September 17th. Don't miss out.

New Content

Subscribe to RSS headline updates from: Journal of Cellular Physiology
Powered by FeedBurner

SEARCH

SEARCH BY CITATION